SRPT
Sarepta Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 Sarepta Therapeutics reported mixed financial results for 2025, with…
- Mar 12 ▼ 1 insider sell $123.2K at $17.02
- Jul 9 ▲ Wolfe Research upgrades
- Nov 5 ▲ Earnings: SRPT Q3 2026 Earnings: EPS $0.13 (+99.4% vs est)
- Nov 10 Trial readout: Results Pending: Eteplirsen (Phase 3), completed 64d ago
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $123.2K.
- InstitutionsMIXED
Q2 2026: 35 added (1 new), 38 trimmed or exited. Largest new: Qube Research & Technologies $11.0M.
- AnalystsMIXED
12 of 31 rate it Buy or better. Median target $20.00 (+32%).
- Short sellersSTEADY
Short interest −13.6% to 19.30M shares. 7.8 days to cover, ≈18.0% of shares.
- TrendDOWNTREND
18% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 26.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $341.3M |
| STATE STREET CORP | ADD | $160.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $150.5M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $49.8M |
| MARSHALL WACE, LLP | DOUBLED | $39.6M |
| GOLDMAN SACHS GROUP INC | ADD | $36.7M |
| UBS Group AG | TRIM | $29.2M |
| NORTHERN TRUST CORP | ADD | $21.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
31 analystsPrice is inside the target range. Median implies +32%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 8, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 5, 2026 | HC Wainwright & Co. REITERATE | Sell |
| Sep 30, 2026 | JP Morgan MAINTAIN | Neutral |
| Sep 28, 2026 | Needham REITERATE | Underperform |
| Jul 9, 2026 | Piper Sandler MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Rodino-Klapac Louise President, R&D and Tech Ops Sep 4, 2026 | TAX W/H | $476.0K |
Rothfuss Cristin EVP, General Counsel Sep 4, 2026 | TAX W/H | $489.4K |
Estepan Ian Michael Chief Operating Officer Sep 4, 2026 | TAX W/H | $551.0K |
Wong Ryan Ho-Yan Chief Financial Officer Sep 4, 2026 | TAX W/H | $294.9K |
SEVERINO MICHAEL Chief Executive Officer Jul 28, 2026 | AWARD | 756,104 sh |
SEVERINO MICHAEL Chief Executive Officer Jul 28, 2026 | AWARD | 2,224,342 sh |
Chambers Michael Andrew Director Jun 4, 2026 | AWARD | 16,875 sh |
Barry Richard Director Jun 4, 2026 | AWARD | 16,875 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 0 bullish · 0 bearish · 2 mixed · 7 neutral- NEUTRAL SC 13G/ANov 13, 2026
AQR Capital Management LLC filed an amended Schedule 13G disclosing a 1.31% passive stake in…
The sharp reduction in AQR's disclosed stake from 7.4% to 1.31% suggests significant selling or a change in reporting methodology. Monitor for any further 13G amendments or a potential conversion to…
- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a new Schedule 13G disclosing a 7.4% passive stake in Sarepta Therapeutics…
State Street's passive 7.4% stake is consistent with index fund and institutional ownership patterns. Monitor the next 13F filing for any material changes in position size, and watch for any future…
- NEUTRAL 8-KNov 5, 2026
The company raised the low end of full-year net product revenue guidance by $50M to $1.25B-$1.3B…
The Q4 2026 MAD data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD) are the next major catalysts; positive results could support Phase 3 advancement and re-rate the stock. The raised revenue…
- NEUTRAL INST-CLUSTERNov 3, 2026
Three asset managers added small positions in Sarepta Therapeutics during Q3 2026, while three…
The cluster shows modest net selling by asset managers with no insider buying to offset it. Monitor upcoming Q3 earnings and any pipeline updates for Sarepta's Duchenne muscular dystrophy therapies…
All SRPT filing & press-release reports (9)
- SC 13G/A reportNov 13, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- 8-K reportJul 27, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 4, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportFeb 25, 2026